{"groups":[{"description":"Pembrolizumab 200mg IV D1 + Romidepsin 14mg/m² IV D1, D8 q21d","id":"FG000","title":"Cohort 1"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"8"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Toxicity"},{"reasons":[{"groupId":"FG000","numSubjects":"16"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"38"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"34"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"This is a phase Ib/II study- and so there is no dose escalation- it was more safety run-in for Ib followed by phase II. There is only one arm since this is a single arm trial."}